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Staphylococcus argenteus is a newly described species, formerly known
as S. aureus clonal complex 75 (CC75). Here, we describe the largest collection of S.
argenteus isolates in North America, highlighting identiﬁcation challenges. We present phenotypic and genomic characteristics and provide recommendations for clinical reporting. Between 2017 and 2019, 22 isolates of S. argenteus were received at 2
large reference laboratories for identiﬁcation. Identiﬁcation with routine methods
(biochemical, matrix-assisted laser desorption ionization–time of ﬂight mass spectrometry [MALDI-TOF MS], 16S rRNA gene analysis) proved challenging to conﬁdently
distinguish these isolates from S. aureus. Whole-genome sequencing analysis was
employed to conﬁrm identiﬁcations. Using several different sequence-based analyses,
all clinical isolates under investigation were conﬁrmed to be S. argenteus with clear
differentiation from S. aureus. Seven of 22 isolates were recovered from sterile sites,
11 from nonsterile sites, and 4 from surveillance screens. While sequence types
ST1223/coa type XV, ST2198/coa type XIV, and ST2793/coa type XId were identiﬁed
among the Canadian isolates, the majority of isolates (73%) belonged to multilocus
sequence types (MLST) ST2250/coa type XId and exhibited a high degree of homology at the genomic level. Despite this similarity, 5 spa types were identiﬁed among
ST2250 isolates, demonstrating some diversity between strains. Several isolates carried mecA, as well as other resistance and virulence determinants (e.g., PVL, TSST-1)
commonly associated with S. aureus. Based on our ﬁndings, the growing body of literature on S. argenteus, the potential severity of infections, and possible confusion
associated with reporting, including use of incorrect breakpoints for susceptibility
results, we make recommendations for clinical laboratories regarding this organism.
KEYWORDS Staphylococcus aureus clonal complex, Staphylococcus argenteus, whole-

genome sequencing, sequence types, MALDI-TOF MS, bacterial identiﬁcation, mecA

S

taphylococcus aureus, including methicillin-resistant S. aureus (MRSA), is one of the
best-studied and -described bacterial pathogens. It is well known to colonize
humans and animals and to cause a range of skin and soft tissue infections, severe
invasive diseases, and toxin-mediated illnesses (1). The rise and dissemination of MRSA
is a major global antimicrobial resistance threat with signiﬁcant clinical and infection
prevention and control (IPAC) implications (2). To properly support clinical decision
making and IPAC interventions, timely and accurate identiﬁcation of S. aureus/MRSA in
the clinical laboratory is imperative.
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There are many clonal complexes and sequence types of S. aureus which are often
used to describe the molecular epidemiology of this pathogen. In 2015, results from
investigations into two staphylococcal species which were almost identical to S. aureus
phenotypically and by 16S rRNA gene sequences gave rise to the formal descriptions
of Staphylococcus argenteus sp. nov., formerly known as S. aureus clonal complex 75
(CC75), and Staphylococcus schweitzeri sp. nov. (3, 4). S. argenteus and S. schweitzeri
each have distinct multilocus sequence types (MLST), and genomic sequence analysis
clearly demonstrates that they are phylogenetically divergent from S. aureus, displaying less than 95% average nucleotide identity (ANI) with one another and a predicted
DNA-DNA hybridization of less than 70% between the species (3, 5–8). S. argenteus and
S. schweitzeri have distinct spectral proﬁles on some research applications and/or databases of matrix-assisted laser desorption ionization–time of ﬂight mass spectrometry
(MALDI-TOF MS), as well as unique cellular fatty acid signatures compared to those of
S. aureus. While S. aureus, S. argenteus, and S. schweitzeri have nearly identical 16S rRNA
gene sequences to one another, there are considerable differences in nuc, which is important given that some of these differences occur in areas of the gene often used as
primer binding sites in PCR assays designed to detect S. aureus (3, 8–10).
S. schweitzeri is considered a zoonotic agent primarily associated with fruit bats
(Eidolon helvum) and monkeys (Cercopithecus ascanius) in Africa (4, 11); that no human
clinical cases have been reported to date suggests that this organism may inhabit a
separate ecological niche from that of S. aureus.
In contrast, S. argenteus has now been established as an effective colonizer and
pathogen of humans (6, 12–20). Initial reports of S. argenteus, both methicillin-susceptible and methicillin-resistant, were from Australia, the Paciﬁc Islands, and Thailand and
were thought to be geographically restricted (3, 5, 6, 13, 21–23). Based on early clinical
observations, S. argenteus was considered less likely to cause nosocomial infections
than S. aureus, appearing to be predominantly associated with community-onset superﬁcial skin lesions (21). Based on this observation and murine studies, and because S.
argenteus lacked some putative S. aureus virulence genes such as staphyloxanthin, the
initial assessment was that S. argenteus was less virulent than S. aureus (7, 21, 24).
Awareness of S. argenteus was heightened after the formal description of the species as well as with the addition of the S. argenteus and S. schweitzeri spectra to the
database of one commonly used commercial MALDI-TOF MS system (RUO database
2018, V8.0, 7854 Bruker; Bruker Daltonics). In the last few years, increased numbers of
clinical reports and descriptions of S. argenteus resulted in increased attention on this
organism and a recognition of a possible global distribution (12, 14–16, 25–30). It is
now also evident that S. argenteus can cause serious invasive disease, including bacteremia, bone and joint infection, and purulent lymphadenitis, and has been directly
linked to patient deaths (13, 16, 18, 19, 30). Like its relative S. aureus, S. argenteus has
been shown to cause toxin-mediated foodborne illnesses (15, 20). In addition to community-associated spread, reports have documented nosocomial spread of S. argenteus
(13, 24). Recent studies have also described strains of S. argenteus harboring traditional
S. aureus virulence factors such as Panton-Valentine leukocidin (PVL), enterotoxins, and
toxic shock syndrome toxin-1 (TSST-1), among others (12, 14, 20, 25, 28, 31, 32).
Considering the clinical and IPAC signiﬁcance of S. argenteus, this organism should
be correctly identiﬁed so that cases are not missed. For greater understanding of clinical, microbiological, and epidemiologic similarities and differences between S. argenteus and S. aureus, the two species should be distinguished. Despite the addition of S.
argenteus spectra to at least one commercial MALDI-TOF MS database, conﬁrmation of
identiﬁcation of and distinction from S. aureus and S. schweitzeri in the clinical laboratory is not straightforward. Laboratories may be identifying S. argenteus as S. aureus, as
these species share equivalent reactions to most key biochemical tests traditionally
used for characterization, such as catalase and tube coagulase positivity and beta-hemolysis on blood agar (3). One exception is that while S. aureus is often (but not exclusively) golden in color, S. argenteus colonies have been found to be nonpigmented,
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appearing white/silver due to the absence of the staphyloxanthin gene cluster
(crtOPQMN) which encodes carotenoid pigment (7). As mentioned previously, 16S
rRNA gene sequence analysis is not able to discriminate between S. argenteus, S. aureus, and S. schweitzeri.
Here, our objective was to verify the identiﬁcations of S. argenteus identiﬁed by
MALDI-TOF MS and characterize the isolates. Using several identiﬁcation methods,
including whole-genome sequencing (WGS), we describe initial isolates of S. argenteus
received at two large North American microbiology reference laboratories, one in
Canada and one in the United States. The description of the microbiological characteristics, including antimicrobial susceptibility proﬁles, of these North American isolates as
well as basic clinical details of the patients contributes to a growing understanding of
the epidemiology and the clinical presentations of this organism. Based on our laboratory experience as well as the growing body of literature on the clinical and IPAC signiﬁcance of S. argenteus, we provide recommendations as to how to report this organism in the clinical laboratory, addressing breakpoint challenges with S. argenteus.

Specimen collections. This study involved a collection of 22 clinical isolates of S. argenteus received
between 2017 and 2019 by two large North American reference laboratories (Public Health Ontario
[PHO], Toronto, ON, Canada [n = 16] and Mayo Clinic, Rochester, Minnesota, USA [n = 6]), along with
strains S. argenteus DSM 28299T/MSHR1132T and S. schweitzeri DSM 28300T/FSA084T. Clinical isolates
were received at the reference laboratories for identiﬁcation and antibiotic susceptibility testing.
Routine identiﬁcation methods for Staphylococcus and related species were conducted, including tube
coagulase, pyrrolidonyl aminopeptidase test (PYR), bacitracin disk, and MALDI-TOF MS (Bruker, BioTyper,
databases V7.0 [7311] used 2017, V8.0 [7854] used 2018, and V9.0 [8468] used 2019) (Table 1). Of note,
BioTyper RUO database V7.0 (7311) did not include S. argenteus or S. schweitzeri for which spectra were
added in the V8.0 (7854) update. For closely related organisms, MALDI-TOF MS (Bruker, BioTyper) can
occasionally result in multiple species scoring at or above the cutoff of .2.0 (conﬁdent to the species
level). Different approaches were employed by each laboratory to avoid potential misidentiﬁcations that
can occur as a result of reporting only the top-scoring identiﬁcation by MALDI-TOF MS. At PHO, 16S
rRNA gene PCR and sequence analysis were performed using universal primer pair 8FPL and 806R (33).
16S rRNA gene sequences were subjected to a BLAST search against the NCBI GenBank type strain and
open nucleotide databases (34) with interpretation criteria described in the Clinical and Laboratory
Standards Institute (CLSI) document MM18-A used to identify the isolates (35). At Mayo Clinic, if multiple
species had scores of $2.0, a score separation of at least 10% was required between the top match and
additional species in order to report the top-scoring organism to the species level. If a $10% score separation was not observed, organisms were only reported to the genus level. This 10% differential rule, or
separation rule, has been used by other groups to aid in differentiating closely related organisms (36,
37).
The S. argenteus strain DSM 28299T (MSHR1132T) and the S. schweitzeri strain DSM 28300T (FSA084T),
inoculated at Mayo Clinic, were used as controls. All isolates were frozen and maintained at 280°C.
Basic characteristics of the patients, including sex, age range, month and year of collection, geographic region, and specimen type, were recorded (Table 1). This work was approved by the PHO
Research Ofﬁce’s Ethics Review Board, and a Privacy Impact Assessment was completed. This work was
also approved by Mayo Clinic’s Institutional Review Board.
Antimicrobial susceptibility testing and determination of MICs. Antimicrobial susceptibility testing was performed by agar dilution according to CLSI guidelines on all isolates to determine MICs (Table
2) (38). D-test for inducible clindamycin resistance and penicillin zone edge test (inducible beta-lactamase) were also performed in accordance with CLSI M100 recommendations (39). Cefoxitin disk (30 m g)
diffusion and a PCR test to detect mecA (with nuc as a positive control for S. aureus) were also performed
(10, 39).
Whole-genome sequencing. Genomic DNA from colonies were extracted and puriﬁed using a
QiaAmp DNA minikit (Qiagen, Valencia, CA) or Zymo Research Quick-DNA Fungal/Bacterial MiniPrep kit
(Zymo Research Corp., CA) from an overnight culture grown aerobically on sheep blood agar according
to the manufacturer’s protocol. The quality of isolated DNA was analyzed using gel electrophoresis and
quantiﬁed using Qubit 2.0 (Invitrogen, Waltham, MA) ﬂuorometer.
DNA libraries were prepared and multiplexed with a unique combination of two indexes of the
Nextera XT index kit (Illumina, San Diego, CA). The sequencing library was quantiﬁed using Qubit 2.0
(Invitrogen, Waltham, MA) and qualiﬁed by Bioanalyzer (Agilent Technologies, Richardson, TX). The
library was normalized and pulled together aiming for an average coverage of 100 and sequenced on
the Illumina MiSeq platform, using Illumina MiSeq reagent kit v2 (2  150 bp), according to the manufacturer’s instructions.
Genome assembly. FastQ ﬁles were imported into CLC Genomics Workbench version 8.0.1 (CLC bio,
Germantown, MD, USA). Raw reads were trimmed to remove Nextera transposase adapter sequences
and assembled using de novo assembler. Following de novo assembly, the largest contig was subjected
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01-2019

01-2019

01-2019

02-2019

03-2019

03-2019

03-2019

11-2019

11-2019

11-2019

08-2019

03-2019

12-2018

02-2019
03-2019
08-2019
2006

Study no.
PHL3431
PHL3432
PHL3433
PHL5740

PHL6344

PHL8605

PHL3446

PHL2420

PHL6318

PHL1144

PHL2411

PHL8642

PHL4815

PHL4226

PHL4313

PHL4553

WU1

WU2

WU3

MC2
MC3
MC4
DSM 28299T
S. argenteus
DSM 28300T
S. schweitzeri

Minnesota, USA
Missouri, USA
Colorado, USA
Northern Territory,
Australia
Moyen-Ogooué,
Gabon

Missouri, USA

Missouri, USA

Missouri, USA

Ontario, Canada

Ontario, Canada

Ontario, Canada

Ontario, Canada

Ontario, Canada

Ontario, Canada

Ontario, Canada

Ontario, Canada

Ontario, Canada

Ontario, Canada

Ontario, Canada

Ontario, Canada

Region
Ontario, Canada
Ontario, Canada
Ontario, Canada
Ontario, Canada

Type strain

Site 8
Site 7
Site 9
Type strain

Site 7

Site 7

Site 7

Site 2

Site 6

Site 6

Site 5

Site 4

Site 2

Site 1

Site 3

Site 2

Site 3

Site 2

Site 2

Submitter
Site 1
Site 1
Site 1
Site 2

Nasal swab
(monkey)

Deep throat
swab (cystic
ﬁbrosis)
Urine
Buttocks wound
Blood
Blood

Buttocks wound

Foot tissue

NA

M
M
M
F

M

M

F

F

M

Synovial ﬂuid
Blood

M

M

M

M

F

M

M

M

M

F

Blood

Head wound

Eye

Rectal & wound
swab
Tendon tissue

Sternal wound

Stump wound

Toe tissue

Wound

Cheek

Site of isolation
Rectal
Nose
Nose
Eye wound

Patient
sex
M
F
M
M

2
2
2
2
2
2
2
2

1
1
1
1
1
1
1
1

NA

2–14
45–54
2–14
55

15–24

15–24

55–64

45–54

55–64

45–54

35–44

NA

45–54

0–1

55–64

65–74

45–54

2

1

$75

2
2
2
2
2
2
2
2
2
2

1
1
1
1
1
1
1
1
1
1

2

1

$75

PYR
2
2
2
2

Tube
coagulase
1
1
1
1

Age
range
$75
$75
$75
55–64

NA

NA
NA
NA
NA

NA

NA

NAg

1

1

1

1

1

1

1

1

1

1

1

1

Bacitracin
disk
1
1
1
1

26

25
25
24
12

25

25

25

32

31

30

26

31

30

28

26

29

29

29

28

Cefoxitin
30 mg disk
(mm zone)a
13
10
11
30

2

2
2
2
1

2

2

2
2
2
2

2

2

2

2
2

2

2

2

2

2

2

2

2

2

2

2

2

2
2

2

2

2

2

2

nuc
PCRb
2
2
2
2

2

2

2

2

2

mecA
PCRb
1
1
1
2

S. argenteus/S. aureus
S. aureus
S. argenteus
S. argenteus/S. schweitzeri/
S. aureush
S. schweitzerih

S. argenteus/S. schweitzeri/
S. aureus
S. argenteus/S. schweitzeri/
S. aureus
S. aureus/S. schweitzeri/
S. argenteus
S. schweitzeri/S. argenteus/
S. aureus
S. argenteus

S. argenteus

S. argenteus/S. schweitzeri

S. argenteus/S. aureus

S. argenteus/S. schweitzeri

S. argenteus/S. schweitzeri/
S. aureus
S. argenteus/S. schweitzeri/
S. aureus
S. argenteus/S. schweitzeri/
S. aureus
S. argenteus

MALDI-TOF MS ID ‡2.0c,d
S. aureus
S. aureus
S. aureus
S. aureus/S. argenteus/
S. schweitzeri
S. argenteus/S. schweitzeri/
S. aureus
S. argenteus

ND

ND
ND
ND
ND

S. argenteus/S. aureus

ND

16S rRNA ‡99%e
NDf
ND
ND
S. aureus/S. argenteus/S.
haemolyticus/S. simiae
S. aureus/S. argenteus/S.
haemolyticus/S. simiae
S. aureus/S. argenteus/S.
haemolyticus
S. aureus/S. argenteus/S.
haemolyticus
S. aureus/S. argenteus/S.
haemolyticus
S. aureus/S. argenteus/S.
haemolyticus/S. simiae
S. aureus/S. argenteus/S.
haemolyticus/S. simiae
S. aureus/S. argenteus/S.
haemolyticus/S. simiae
S. aureus/S. argenteus/S.
haemolyticus/S. simiae
S. aureus/S. argenteus/S.
haemolyticus
S. aureus/S. schweitzeri/S.
argenteus/S. haemolyticus
S. argenteus/S. aureus/S.
schweitzeri/S. haemolyticus
S. argenteus/S. aureus/S.
schweitzeri/S. haemolyticus
ND
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aFor

S. aureus, cefoxitin disk (30 m g disk content) zone diameter breakpoints $22 mm susceptible and #21 mm resistant; for other Staphylococcus spp. (excluding S. aureus, S. lugdunensis, S. pseudintermedius, S. schleiferi, S.
epidermidis), zone diameter breakpoints $25 mm susceptible and #24 mm resistant (CLSI M100 2020).
bqPCR assay by Pichon et al. (10).
cBruker MALDI BioTyper, databases: 2017, V7.0 (7,311 entries); 2018, V8.0 (7,854 entries), and 2019, V9.0 (8,468 entries). The identiﬁcations presented are those at the initial time of testing with the database that was in use at the
time.
dMatches presented by descending score (top hit listed ﬁrst).
ePartial 16S rRNA gene sequence (;700 bp) BLAST NCBI type strain database, presented by descending max score.
fNot done.
gNot available.
hResults with Bruker MALDI BioTyper database V9.0 (8,468 entries).

2010

Date of
isolation
(mo-yr)
10-2017
10-2017
10-2017
10-2018

TABLE 1 Initial characteristics

Eshaghi et al.
Journal of Clinical Microbiology
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to NCBI BLAST to select the closest matching complete S. argenteus genome in GenBank to serve as the
reference for reference-based assembly using CLC Genomic Workbench 8.5.3 (QIAGEN Digital Insights).
Genome analysis. The assembly was annotated using the RAST server (http://rast.nmpdr.org) (40)
for gene prediction and annotation. Genome sequencing data of each isolate was assessed for in silico
identiﬁcation of MLST, SCCmec, and plasmid replicon and resistance genes using online tools such as
CARD (41), MLST-1.8 server (42), ResFinder 2.1 (43), and SCCmecFinder 1.2 server (44) available by Center
for Genomic Epidemiology (http://genomicepidemiology.org). Virulence factors (VFs) were identiﬁed by
using VFanalyzer of the virulence factor database (VFDB) (http://mgc.ac.cn/VFs/) (45). To identify plasmids, the genome assemblies were screened using PlasmidFinder database for plasmid replicon (rep)
genes (46).
Single nucleotide variant (SNV) analysis was conducted using a custom pipeline. Brieﬂy, reads for all
isolates were mapped against the chromosome of the strain MSHR1132T (DSM 28299T) available in
GenBank (accession number NC_016941.1) for reference using SMALT software v 0.7.6 (https://www
.sanger.ac.uk/tool/smalt-0/). Single nucleotide polymorphism (SNP) calling was performed using
Freebayes with min-base-quality 30, min-mapping-quality 30, min-alternate-fraction 0.75, read-snp-limit
10, and min-coverage 15 (47). Additional variant conﬁrmation was done using the SAMtools mpileup
tool (48). Repetitive regions were removed by using MUMmer (49). The meta-alignment of core informative positions (SNVs) was used to create a maximum likelihood (ML) tree using MEGA 6 (50).
A whole-genome phylogenomic approach was performed by uploading the assembled sequences
to Type Strain Genome Server (TYGS; https://tygs.dsmz.de) for a whole-genome-based phylogenetic
analysis of isolates to the most closely related genome database (51).
ANI was calculated using EZBioCloud ANI calculator (52) between assembled genomes obtained in
this study and publicly available genomes of S. argenteus MSHR1132T (accession number NC_016941.1),
S. argenteus strain XNO62 (accession number CP023076.1), S. schweitzeri NCTC 13712T (accession number
NZ_LR134304.1), and S. aureus NCTC 8325 (accession number NC_007795.1). An ANI threshold of $96%
was considered to be the cutoff for species identiﬁcation, which correlates to DNA-DNA hybridization
studies (53). Whole-genome comparison was performed and visualized using the Gview tools (54).
spa typing, Sanger protocol. All S. argenteus in this study were subjected for spa sequence-based
typing using the previously published PCR primers (55). spa amplicons were sequenced with the same
primers and analyzed using the spa type ﬁnder/identiﬁer (http://spatyper.fortinbras.us) and the Ridom
SpaServer (https://spaserver.ridom.de).
Data availability. WGS sequence data are available in the following databases. NCBI (https://www
.ncbi.nlm.nih.gov/): accession numbers QQOV00000000 (PHL3431), PUXC00000000 (PHL3432), and
QQOW00000000 (PHL3433). BioProject accession number PRJNA666697: WGS numbers JADANH000000000
(PHL6344), JADANG000000000 (PHL5740), JADANF000000000 (PHL3446), JADANE000000000 (PHL2420),
JADAND000000000 (PHL6318), JADANC000000000 (PHL8605), JADANB000000000 (PHL2411), JADANA000000000
(PHL1144), JADAMZ000000000 (PHL4815), JADAMY000000000 (PHL8642), JADAMX000000000 (PHL4226),
JADAMW000000000 (PHL4313), JADAMV000000000 (PHL4553), JADAMU000000000 (DSM 28299T),
JADAMT000000000 (DSM 28300T), JADAMS000000000 (MC2), JADAMQ000000000 (MC3), JADAMP000000000
(MC4), JADAMO000000000 (WU1), JADAMN000000000 (WU2), and JADAMR000000000 (WU3).

RESULTS
Initial description of isolates. In total, 22 isolates were received at the PHO laboratory (n = 16) and Mayo Clinic (n = 6) for conﬁrmation of identiﬁcation of S. aureus,
MRSA, or S. argenteus from 2017 to 2019 (Table 1). All isolates were tube coagulase
positive and PYR negative.
The initial 3 S. argenteus isolates arrived at the PHO laboratory in 2017, as MRSA
isolates (PHL3431, PHL3432, and PHL3433) for conﬁrmation of identiﬁcation. At the
time, MALDI-TOF MS provided conﬁdent identiﬁcations of S. aureus ($2.0), with
positive tube coagulase and PYR reactions; of note, the BioTyper RUO database
V7.0 (7311) used at the time did not include S. argenteus or S. schweitzeri. To determine the presence of mecA and conﬁrm the identiﬁcation of MRSA, these isolates
were run on an in-house mecA PCR assay (10). All three isolates were positive for
mecA; however, the positive control for S. aureus, nuc, was negative (Table 1). These
results prompted further investigation of the identiﬁcation of the organisms, and
they were referred for WGS analysis, which determined that they were S. argenteus
(details below).
In 2018, the Bruker BioTyper RUO database was updated to include spectra for S.
argenteus and S. schweitzeri for the ﬁrst time (RUO databases V8.0 [7854 MSP] and V9.0
[8468]), after which both reference laboratories were technically able to use MALDITOF MS to identify S. argenteus and S. schweitzeri. When the single S. schweitzeri strain
available in this study (DSM 28300T) was tested by MALDI-TOF MS using the new databases, it resulted in a single identiﬁcation of $2.0 of S. schweitzeri; of note, this same
strain was used to produce the spectrum in the library (Table 1). However, use of the
June 2021 Volume 59 Issue 6 e02470-20
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$32
$32
$32
#8
#8
#8
#8
#8
#8
#8

#8
#8
#8
#8
#8
#8
NA
NA
NA
NA

NA
NA
NA

NA

Ampicillin

$16b
$16
$16
#8
#8
#8
#8
#8
#8
#8

#8
#8
#8
#8
#8
#8
NA
NA
NA
NA

NA
NA
NA

NA

Isolate no.
PHL3431
PHL3432
PHL3433
PHL5740
PHL6344
PHL8605
PHL3446
PHL2420
PHL6318
PHL1144

PHL2411
PHL8642
PHL4815
PHL4226
PHL4313
PHL4553
WU1
WU2
WU3
MC2

MC3
MC4
S. argenteus
DSM 28299T
S. schweitzeri
DSM 28300T

Ciprofloxacin

Clindamycin

Erythromycin
Gentamicin
#2
#2
#2
#2
#2
#2
#2
#2
#2
#2

#2
#2
#2
#2
#2
#2
#2
#2
#2
#2

Linezolid
#0.12
0.5
#0.12
#0.12
4
0.5
#0.12
#0.12
#0.12
4

8
8
8
4
4
#0.12
#0.12
#0.12
#0.12
4
#4
#4
#4
#4
#4
#4
#4
#4
#4
#4

#4
#4
#4
#4
#4
#4
#4
#4
#4
#4
#2/38
#2/38
#2/38
#2/38
#2/38
#2/38
#2/38
#2/38
#2/38
#2/38

#2/38
#2/38
#2/38
#2/38
#2/38
#2/38
#2/38
#2/38
#2/38
#2/38
1
1
1
1
1
1
2
2
2
2

1
1
1
1
1
1
1
1
1
1

#2 #0.12 #4 #2/38 1

#4
#4
#4
#4
#4
#4
#1
#1
#1
#1

#4
#4
#4
#4
#4
#4
#4
#4
#4
$16

Penicillin

NA #0.5 #0.5 #1

#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5

#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5

Tetracycline

#2 #0.12 #4 #2/38 2
#2 #0.12 #4 #2/38 1
#2 8
#4 #2/38 1

#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5

#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5

Vancomycin

NA #0.5 #0.5 #1
NA #0.5 #0.5 #1
NA #0.5 #0.5 #1

#1
#1
#1
#1
#1
#1
NA
NA
NA
NA

$4
$4
$4
#1
#1
#1
#1
#1
#1
#1

Ceftaroline
0.25

0.25
0.25
0.5

0.25
#0.12
0.25
0.25
0.25
0.25
0.25
0.25
#0.12
0.25

1
NA
0.5
0.25
0.25
0.25
#0.12
0.25
#0.12
0.25

Levofloxacin
#1

#1
#1
#1

#1
#1
#1
#0.5
#0.5
#0.5
#1
#1
#1
#1

#1
NA
1
#1
#1
#1
#1
#1
#1
#1

Mupirocin

Minocycline
#4
#4
#4
#4
#4
#4
#4
#4
#4
#4

#4
NA
#4
#4
#4
#4
#4
#4
#4
#4

Nitrofurantoin
#32
#32
#32
#32
#32
#32
#32
#32
#32
#32

#32
NA
#32
#32
#32
#32
#32
#32
#32
#32

Rifampin
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5

#0.5
NA
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5
#0.5

Doxycycline
#4
#4
#4
#4
#4
#4
#4
#4
#4
#4

#4
NA
#4
#4
#4
#4
#4
#4
#4
#4

Delafloxacin
#0.008
#0.008
#0.008
#0.008
#0.008
#0.008
#0.008
#0.008
#0.008
#0.008

0.12
NA
0.12
#0.008
#0.008
#0.008
#0.008
#0.008
#0.008
#0.008

Oxacillin
#0.25
#0.25
#0.25
#0.25
#0.25
#0.25
#0.25
#0.25
#0.25
1

.2
NA
.2
1
1
#0.25
#0.25
#0.25
#0.25
1

NA
NA
2
2
2
NA
2
2
2
2

#256 #4 #32 #0.5 #4 #0.008 #0.25 2

2

2
2
1

2
NA
NA

NAc
NA
NA
NA
NA
2
2
2
NA
NA
2
2
2

2
NA
2
2
2
2
2
2
2
2

D-test

#256 #4 #32 #0.5 #4 #0.008 #0.25 2
#256 #4 #32 #0.5 #4 #0.008 #0.25 2
#256 #4 #32 #0.5 #4 #0.008 .2
2

#256
#256
#256
#256
#256
#256
#256
#256
#256
#256

#256
NA
#256
#256
#256
#256
#256
#256
#256
#256

Penicillin zone edge test
(inducible beta-lactamase)
CARD resistance database (genes)
mgrA, arlR, mepR, lmrS, fosB, mecA
mgrA, arlR, mepR, lmrS, fosB, mecA
mgrA, arlR, mepR, lmrS, fosB, mecA
mgrA, arlR, mepR, lmrS, fosB, blaZ
mgrA, arlR, mepR, lmrS, fosB, blaZ
mgrA, arlR, mepR, lmrS, fosB
mgrA, arlR, mepR, lmrS, fosB
mgrA, arlR, mepR, lmrS, fosB
mgrA, arlR, mepR, lmrS, fosB
mgrA, arlR, mepR, lmrS, fosB, blaZ,
AAC(69)-Ie-APH(29')-Ia
mgrA, arlR, mepR, lmrS
mgrA, arlR, mepR, lmrS, blaZ
mgrA, arlR, mepR, lmrS, fosB
mgrA, arlR, mepR, lmrS, fosB
mgrA, arlR, mepR, fosB, lmrS, blaZ
mgrA, arlR, lmrS, blaZ
mgrA, arlR, mepR, lmrS, fosB
mgrA, arlR, mepR, lmrS, fosB
mgrA, arlR, mepR, lmrS, fosB
mgrA, arlR, mepR, lmrS, fosB,
blaZ, fusB
mgrA, arlR, mepR, lmrS, fosB
mgrA, arlR, mepR, mexT, lmrS, fosB
mgrA, arlR, mepR, lmrS, fosB,
mecA, blaZ
mgrA, arlR, mepR, lmrS, murA
with mutation

jcm.asm.org 6

Downloaded from https://journals.asm.org/journal/jcm on 24 September 2021 by 128.252.218.198.

were obtained by CLSI agar dilution method, with the exception of delaﬂoxacin for which agar dilution was performed on all isolates at Mayo Clinic and D-test was performed on all isolates at Mayo Clinic by the disk
diffusion method.
bBold, underlined MICs indicate resistance according to CLSI M100 (39) using S. aureus breakpoints.
cNA, not available.

aMICs

Cefazolin

MIC (mg/ml)a

Trimethoprimsulfamethoxazole

TABLE 2 Antibiotic susceptibility test results (phenotypic and genomic)

Eshaghi et al.
Journal of Clinical Microbiology

Journal of Clinical Microbiology

updated databases challenged with S. argenteus typically resulted in multiple species
(S. aureus, S. argenteus, and S. schweitzeri) with high ($2.0) scores (Table 1), resulting in
an inability to conﬁdently identify the organism to species level. This prompted additional testing to conﬁrm identiﬁcation, including attempts at using 16S rRNA gene
sequence analysis.
Partial 16S rRNA gene PCR and sequence analysis of these isolates were not able to
reliably differentiate between S. aureus, S. argenteus, and S. schweitzeri as well as a
strain of Staphylococcus haemolyticus (accession number Z26896.1); all had $99.0%
homology to reference strain deposits within NCBI GenBank for these species (Table 1).
Of note, S. haemolyticus could be ruled out as it is coagulase negative, and Z26896.1
was likely deposited into NCBI incorrectly.
Isolates were also tested with the in-house nuc quantitative PCR (qPCR) in which the
primers are speciﬁc to S. aureus (10) (the nuc target is used as a control for S. aureus in a
mecA PCR assay). All isolates of S. argenteus for which the described nuc qPCR assay was
run were negative (Table 1), while control isolates of S. aureus were positive (data not
shown). While this result is evidence that the isolates under investigation were not S. aureus, the negative results of this assay do not speciﬁcally identify S. argenteus and cannot
rule out S. schweitzeri. The lack of deﬁnitive identiﬁcation prompted the use of WGS.
Patient demographics and specimen descriptions. S. argenteus isolates were cultured from patients in Ontario, Canada (n = 16), Missouri (n = 4), Minnesota (n = 1), or
Colorado (n = 1) and identiﬁed between October 2017 and November 2019. Detailed
patient information for these isolates was not available. Of the 22 isolates described, 7
were from sterile sites, 11 from nonsterile sites, and 4 from surveillance screens.
Seventy-seven percent (n = 17) were recovered from males and 23% (n = 5) from
females. Ages of patients ranged from ,1 to $75 years (Table 1).
Phenotypic antimicrobial susceptibility. MICs for all isolates and antibiotics tested
are presented in Table 2. All S. argenteus identiﬁed in this collection demonstrated low
MICs to clindamycin, erythromycin, linezolid, trimethoprim-sulfamethoxazole, and vancomycin and would be considered susceptible using S. aureus breakpoints (39). Ten of
22 (45.4%) isolates were resistant to penicillin (MIC range 0.5 to 8 m g/ml); 3 of these isolates (PHL3431, PHL3432, PHL3433) were also mecA PCR positive, demonstrating oxacillin MICs of .2 m g/ml (PHL3431, PHL3433) and resistance to ciproﬂoxacin. S. argenteus
isolates with penicillin MICs of #0.12 m g/ml were negative by the penicillin zone edge
test. One isolate (PHL1144) was resistant to gentamicin with an MIC of 16 m g/ml.
As there are different oxacillin breakpoints for different Staphylococcus species (39),
we evaluated multiple species-speciﬁc breakpoints for oxacillin susceptibility testing.
Using S. aureus breakpoints, 3 of 21 isolates (14.3%) would be considered oxacillin resistant, while when using the “other Staphylococcus species” breakpoints, 7 of 21
(33.3%) would be considered resistant. All S. argenteus isolates identiﬁed as oxacillin resistant using S. aureus breakpoints harboring mecA (as determined by mecA-speciﬁc
qPCR as well as WGS analysis). PHL3432 was identiﬁed as being mecA positive but was
not subjected to oxacillin susceptibility testing due to strain loss.
Genome features and comparative genomics. De novo assembly of sequence
reads using CLC Genomics Workbench resulted in 1,610,728 to 7,425,408 bp.
Between 12 and 315 contigs were obtained, with the largest contig size of
1,088,191 bp length and average coverage of 153. The N50 values of assemblies
were 23,043 to 693,825 bp.
The sequences of all 23 S. argenteus (22 clinical isolates and 1 type strain, DSM
28299T) and 1 S. schweitzeri genome (DSM 28300T) were assembled by mapping short
reads to the reference sequence XNO62 (accession number CP023076.1). Assembled
genomes ranged from 2,599,989 to 2,724,271 bp in size with a GC content of 32.42%.
Genome annotation by RAST showed an average of 2,665 (median 2,603) coding
sequences and average of 63 RNAs (tRNAs and rRNAs) among all S. argenteus. De novo
assembly of 4,014,380 reads obtained for type strain S. schweitzeri (DSM 28300T)
resulted in 37 contigs between 200 and 343,130 bp; the assembled genome was
June 2021 Volume 59 Issue 6 e02470-20
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2,784,939 bp long with 305 coverage and N50 of 200,036. Using RAST annotation,
2,885 coding DNA sequences (CDSs) and 65 RNAs (tRNAs and rRNAs) were identiﬁed.
The clinical isolates’ pairwise ANI values between isolates studied and S. argenteus
XNO62 (accession number CP023076.1) were 98.70 to 99.96% and were 92.61 to
92.23% and 87.58 to 89.0% compared against S. schweitzeri and S. aureus, respectively
(see Table S1 in the supplemental material).
A circular alignment of genomes from this study compared with reference genomes
S. argenteus XNO62 and MSHR1132T is presented in Fig. S1. This alignment, as well as
other features such as sequence similarity and distribution of GC content, demonstrated a high level of homology among members of these groups.
The WGS data for all 22 clinical isolates were interrogated for MLST and other features commonly used for typing S. aureus. Four MLSTs were identiﬁed in the collection:
ST2250 (16/22) predominated, followed by ST1223 (3/22), ST2198 (2/22), and ST2793
(1/22) (Fig. 1A). MLSTs for type strains of S. argenteus (DSM 28299T) and S. schweitzeri
(DSM 28300T) were determined to be ST1850 and ST2022, respectively, as previous
described (3). Using Basic Local Alignment Search Tool (BLAST; https://blast.ncbi.nlm
.nih.gov/Blast.cgi) on extracted staphylocoagulase (coa) sequences from assemblies,
three coa types were identiﬁed: XId, XV, and XIV, with coa-type XId being the predominant type (17/22) (Fig. 1A). We were unable to assign spa type from in silico whole-genome data due to the repetitive region span being greater than the read length of
150 bp. Using traditional endpoint PCR and Sanger sequencing, we were able to conﬁrm presence of at least 8 spa types among clinical isolates of S. argenteus in this study.
All mecA-positive S. argenteus identiﬁed in this study (3/22) were assigned the spa type
t7960, while the majority of isolates were spa type t5078 (9/22). Other spa types identiﬁed include t10900 (1/22), t9385 (2/22), and 3 novel spa types, t19456 (1/22), t19457
(1/22), and t19497 (2/22). We were unable to assign a spa type to 3 isolates, all of which
belonged to ST1223 (https://spa.ridom.de/spatypes.shtml) (Table S2). Strains DSM
28299T and DSM 28300T were t17252 and t6705, respectively.
Phylogenetic relationships of S. argenteus genomes were assessed using core genome SNV as well as whole-genome sequence analysis, with both methods yielding
phylogenetic trees with similar topologies. Examination of clinical isolates as well as
the strain DSM 28299T resulted in 5 clusters of S. argenteus which coincided with the 5
MLSTs (WGS phylogenetic tree shown in Fig. 1, SNV tree not shown). The major cluster
was comprised of 16 isolates (10 from Canada and 6 from the United States), all MLST
2250, with little variation in the core genome (0.2 to 0.3%).
The full lengths of S. argenteus, S. aureus, and S. schweitzeri 16S rRNA and nuc genes
were extracted from the assemblies. As shown before by others, our results demonstrate that there is insufﬁcient demarcation between the 16S rRNA gene of these three
species to be used for species identiﬁcation (Fig. S1). However, the nuc gene allows for
clear separation of the three species (Fig. 2) (3, 8, 9).
Antibiotic resistance determinants identiﬁed through WGS analysis. A total of 9
antibiotic resistance genes were identiﬁed among the 22 S. argenteus clinical isolates;
each isolate harbored multiple genes associated with resistance (Table 2). Genes identiﬁed include mecA (3/22), mgrA (norR) and arlR (both 22/22) (encode regulatory components for a major facilitator superfamily [MFS] antibiotic efﬂux pump associated with
ﬂuoroquinolone, tetracycline, penicillin, cephalosporin, and peptide antibiotic resistance) (56, 57), mepR (21/22) (encodes a repressor that helps to regulate expression of a
multidrug and toxic compound extrusion [MATE] efﬂux pump [58, 59]), blaZ (7/22)
(encodes class A b -lactamase) (60), fosB (18/22) (encodes a fosfomycin thiol transferase
which inactivates fosfomycin) (61), lmrS (22/22) (encodes a component of an MFS efﬂux
pump associated with resistance to several antibiotics, including macrolides, aminoglycosides, diaminopyrimidines, and oxazolidinones) (62), and aac(69)-Ie-aph(29')-Ia (1/22)
(encodes an aminoglycoside-modifying enzyme which inactivates aminoglycoside,
including gentamicin) (63). As demonstrated in Table 2, many of these molecular determinants of resistance correlated with phenotypic resistance. Further analysis of isolates
June 2021 Volume 59 Issue 6 e02470-20

jcm.asm.org 8

Downloaded from https://journals.asm.org/journal/jcm on 24 September 2021 by 128.252.218.198.

Eshaghi et al.

Journal of Clinical Microbiology

FIG 1 Whole-genome sequence phylogenetic tree of S. argenteus. (A) Whole-genome sequence phylogenetic tree of S. argenteus from this study and
related type strains of the genus Staphylococcus obtained from TYGS. Tree inferred with FastME 2.1.6.1 from Genome BLAST Distance Phylogeny

(Continued on next page)
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with mecA showed that their SCCmec type IV possesses the class B mec gene complex,
harboring the mecA, mecR1, IS1272, and ccrA/ccrB gene complex (Fig. 1A).
Given a recent report of daptomycin resistance in S. argenteus associated with a
point mutation in mprF, we analyzed the predicted protein of this gene in all isolates
of this study and found all to be wild type (S337, data not shown) (30).
As plasmids often carry antibiotic resistance determinants, we investigated the
presence of plasmids using genomic analysis. Using the PlasmidFinder, a total of 7
plasmid replicon types were detected in our isolates, characterized as rep16, rep5,
repUS5, rep5a, repUS9, rep20, and rep21 with accession numbers BX571858,
NC005011, NC003265, AP003139, AF203376, FN433597, and NC007790, respectively, with an alignment similarity ranging from 99.24 to 100%. The S. argenteus
isolates in this study were found to harbor multireplicons in various combinations,
including rep16/rep5, rep16/rep5a, rep16/repUS5, rep16/rep5/repUS9, and rep21/
rep20 (Table S2).
Putative virulence determinants. Analysis of putative virulence gene composition based on the VF database revealed a number of virulence determinants in all S.
argenteus isolates from this study, including autolysin (atlE), elastin binding protein
(ebp), ﬁbrinogen binding protein (efb), intercellular adhesion (icaA, icab, icaC, and
FIG 1 Legend (Continued)
approach (GBDP) distances calculated from genome sequences. The branch lengths are scaled in terms of GBDP distance formula d5. The numbers
above branches are GBDP pseudo-bootstrap support values .60% from 100 replications. The reference sequences available in GenBank and the type
strains sequenced in this study are indicated by solid black and blue dots, respectively. The tree was rooted at the midpoint. Staphylocoagulase (coa),
SCC mec IV (2B), mecA, ccrA and ccrB, IS1272, PVL, TSST, MLST, and spa type are indicated for each strain. Presence of a given gene/element is identiﬁed
by colored boxes. NT, nontypable. (B) Magniﬁed main branch of phylogenetic tree containing S. argenteus representing clustering of strains possessing
same MLST. *, sequences for these type strains (DSM 28229T, DSM 28300T) were generated in this study; #, novel spa types identiﬁed in this study.
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FIG 2 nuc phylogenetic tree. Phylogenetic dendrogram of nuc sequences of S. argenteus from this study and S. argenteus, S. schweitzeri, and S. aureus
strains from GenBank constructed by neighbor-joining method. The evolutionary distances were computed using the maximum composite likelihood
method and are in the units of the number of base substitutions per site. The analysis involved 125 isolates. There were a total of 426 positions in the ﬁnal
data set. Evolutionary analyses were conducted in MEGA6. Green text, S. argenteus; red text, S. schweitzeri; blue text, S. aureus; black diamond, genome
sequence of type strains generated in this study; black square, genome sequence of type strains obtained from GenBank; red circles, sequences from PHO
isolates; blue circles, sequences from Mayo Clinic isolates.

icaR), staphylokinase (sak), staphylococcal complement inhibitor (scn), staphylococcal
protein A (spa), cysteine protease (sspB), hyaluronate lyase (hysA), lipase (geh and lip),
staphylocoagulase (coa), thermonuclease (nuc), capsular (cap5 and cap8), type VII
secretion system (esaG, essA, essB, essC, and esxA), alpha hemolysin (hly/hla), delta hemolysin (hld), exfoliative toxin type A (eta), and gamma hemolysin (hlgA, hlgB, and
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DISCUSSION
Through many reports over the past several years, including this one, it is clear that
S. argenteus is a distinct species from S. aureus and that it is clinically relevant as a
cause of skin and soft tissue infections as well as severe invasive disease (3, 7, 12–14,
16–19, 23, 24, 64). Several reports have indicated international detection of S. argenteus
(12, 14–16, 25–29, 65–68); here, we report the ﬁrst large collection of clinical isolates of
S. argenteus in North America, from both Canada and the United States. As large reference laboratories, we each receive isolates to conﬁrm bacterial identiﬁcation. From
2017 to 2019, collectively, we received and identiﬁed 22 isolates of S. argenteus.
We encountered some of the same initial challenges as other investigators in the
differentiation of S. argenteus from S. aureus using both traditional biochemical assays
and a commercial MALDI-TOF MS (Bruker Biotyper) system, despite having spectra for
both S. argenteus and S. schweitzeri in the databases. Although not investigated here,
another commercial MALDI-TOF MS system (Vitek MS, bioMérieux) does not currently
have spectra for S. argenteus or S. schweitzeri, and users of this system may erroneously
call these organisms S. aureus. Further investigation must be undertaken concerning
the ability of commercial MALDI-TOF MS platforms and database/software versions to
differentiate among the S. aureus complex members. At this time, current routine
methods used in clinical microbiology laboratories will not conclusively differentiate S.
argenteus from S. aureus.
All S. argenteus encountered during this investigation period were deﬁnitively identiﬁed using a WGS approach. Our WGS data are consistent with previous reports that S.
argenteus is distinct from S. aureus and S. schweitzeri (3, 7, 14, 25, 69). All isolates of S.
argenteus for which the described nuc PCR assay was run were negative, while isolates
of S. aureus were positive (data not shown) (10); however, depending on where the primers are, this may not always be the case. The nuc sequences examined demonstrate
considerable sequence diversity between S. aureus, S. argenteus, and S. schweitzeri, consistent with what other investigators have found (3, 8, 9, 14, 70). This sequence diversity can be exploited as with the appropriate primers the nuc gene can be a target for
discriminating S. aureus from other members of the complex, thus avoiding the need
for WGS to distinguish S. aureus from S. argenteus/S. schweitzeri. An example of such an
assay is the one developed by the Mayo Clinic (71). As many laboratories already
include a nuc target in their mecA PCR as a control, this may not require signiﬁcant
workﬂow changes. Other groups have identiﬁed crtM and sodA as useful targets for differentiating these species (29, 72).
S. argenteus from this collection were isolated from a range of sites, including normally
sterile and nonsterile specimen sources, and from surveillance swabs. Patients ranged in
age from ,1 to $75 years, with most being older than 45 years of age. One limitation of
this study is that we do not have detailed information on the patients, including if they
were inpatients or outpatients and whether the S. argenteus was likely acquired in the
community or via a nosocomial route. It is possible that 3 isolates in this study were part
of a nosocomial transmission event, as these isolates were collected from patients being
investigated as part of a MRSA cluster in a health care facility (PHL3431, PHL3432, and
PHL3433). These three isolates were identiﬁed through surveillance screens and are all
temporally related from the same health care facility; all were mecA-positive ST2250, spa
type t7960, SCCmec type IV (2B) with similar antimicrobial susceptibility patterns and
were $99.94% similar to one another by ANI comparison. Another limitation of this work
is that we have no treatment or clinical outcome data on these patients. This type of information needs to be collected to better understand the transmission dynamics,
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hlgC) genes (Table S3). Additionally, one clinical S. argenteus isolate (WU3, a throat
swab isolate) harbored the gene that encodes Panton-Valentine leukocidin (PVL), and
another single isolate (MC4, a blood isolate) harbored the gene for toxic shock syndrome toxin (TSST-1).
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reservoirs, and best treatment options for patients; however, in order for this to be done,
widespread, accurate identiﬁcation of S. argenteus must be available.
This study is unique in that it includes a large number of S. argenteus isolates from
North America, from both Canada and the United States. Although it has been postulated to have spread globally, this is the ﬁrst report to demonstrate that S. argenteus is
present in North America beyond a single case report and is likely circulating (30). Like
many global studies, the majority of isolates (73%) in this study belong to MLST
ST2250 (14, 16, 18, 19, 23, 32, 65, 73). These ST2250 isolates were also part of coa XId,
described as the predominant type by Aung et al. in their study (69). There was a high
degree of homology among these ST2250/coa XId isolates; however, 5 different spa
types were identiﬁed, showing some diversity between strains.
Three additional previously reported but less frequently described MLSTs (ST1223,
ST2198, and ST2793) were identiﬁed from the Canadian specimens, with corresponding coa types XV, XIV, and XId, respectively, thus demonstrating some diversity in the
North American isolates (14, 16, 23, 25, 31, 32, 69, 72, 74–77). Most isolates in this study
belonged to the coa types XIV and XV. spa typing is based on the highly variable and
repetitive X-region of a single gene (spa) that encodes protein A. Use of reads generated by WGS in order to infer spa type has been done for S. aureus; however, factors
such as length of the reads and repetitive sequence regions affect the de novo assembly and may result in incorrect assignments of spa type. To overcome these challenges,
here we relied on traditional Sanger sequencing to conﬁrm spa types and identiﬁed 7
different spa types, including 3 previously undescribed types (all in ST1223 isolates),
adding evidence of the diversity of this collection of S. argenteus. A wide array of virulence determinants commonly associated with S. aureus were also detected, with PVL
and TSST-1 of note. Further detailed investigation of isolates is needed to truly understand the diversity and epidemiology of the organism in North America.
It is interesting to consider why this organism appears to be emerging at this time.
It is possible that S. argenteus, as part of the S. aureus clonal complex, has always been
a human pathogen and had gone undetected until recently due to implementation of
newer, more speciﬁc identiﬁcation methods (e.g., WGS). However, others have provided evidence that supports a fairly recent host adaption which has allowed it to colonize and infect humans (the same does not appear to have happened with the closely
related S. schweitzeri, for which there are no reports of human infection) (25, 75).
Regardless of whether it is a newly emergent pathogen or an organism that we can
only now differentiate from S. aureus, it is clear that S. argenteus is pathogenic and possesses many of the same virulence determinants and resistance mechanisms (including
mecA) as S. aureus. Based on our experience as well as the emerging ﬁndings reported
in the literature, we support the proposal that S. argenteus should be treated in a similar manner as S. aureus in terms of IPAC measures, as well as clinically, for the following
reasons: (i) evidence points to similar disease presentations (including invasive disease), (ii) there is evidence of both community and nosocomial spread, and (iii) S.
argenteus, like S. aureus, can carry mecA, PVL, TSST-1, and other virulence genes, suggesting it has similar pathogenic potential (78).
Clinical laboratories and other members of the health care teams should recognize
that S. argenteus and S. schweitzeri are members of the S. aureus complex; this is signiﬁcant, as classiﬁcation guides appropriate clinical interpretation of culture as well as
oxacillin susceptibility. If the oxacillin MIC breakpoints of the non-S. aureus group (S #
0.25 m g/ml; R $ 0.5 m g/ml) are assigned to S. argenteus instead of S. aureus oxacillin
MIC breakpoints (S # 2 m g/ml; R $ 4 m g/ml), isolates may be inappropriately reported
as oxacillin resistant (39). Likewise, cefoxitin disk diffusion breakpoints differ between
these two groups. Furthermore, allowable methods for detection of methicillin resistance differ according to Staphylococcus species; for example, cefoxitin MIC is an appropriate testing method for S. aureus, while it is not appropriate for the “other
Staphylococcus spp.” group. Given that S. argenteus appears to be more like S. aureus
than other staphylococci applying the genomic, phenotypic, and clinical data to date,
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